Related Experiment Video
Updated: May 24, 2026

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
Published on: April 26, 2017
RNA splicing in cancer cell death regulation: shedding light on the molecular mechanisms and potential clinical
Minghui Song1, Yaru Wang1, Haiyun Zhang1
1School of Pharmacy and Department of Hepatology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, PR China.
Abstract:
Alternative splicing (AS) is a ubiquitous posttranscriptional regulatory mechanism in eukaryotes through which proteins with various structures and functions are produced from a single pre-mRNA. It is performed by the spliceosome and regulated by both cis-acting elements and trans-acting splicing factors. The common modes of regulatory cell death (RCD) include apoptosis, necroptosis, autophagy, pyroptosis and ferroptosis, and dysregulation of these cell death modes can lead to tumorigenesis. The abnormal expression of spliceosome components and splicing factors, or aberrant splicing events, modulates RCD and contributes to the occurrence and progression of cancer. This review focuses on the roles of AS in tumour RCD and the underlying mechanism through which AS modulates different modes of RCD. Moreover, we summarise some potential clinical applications of targeting AS-RCD axes. This review offers systematic and mechanistic insights into tumorigenesis from the perspectives of AS and RCD, and the ultimate objective is to translate these findings into targeted therapies for cancer treatment.
Insights
Alternative splicing (AS) regulates cell death, impacting cancer development. Targeting AS-mediated regulatory cell death (RCD) offers potential new cancer therapies.
Area of Science:
- Molecular Biology
- Cell Biology
- Oncology
Background:
- Alternative splicing (AS) generates protein diversity from a single gene via the spliceosome.
- Dysregulation of regulatory cell death (RCD) pathways like apoptosis and ferroptosis is linked to cancer.
- Aberrant AS events involving spliceosome components and splicing factors can influence RCD and contribute to tumorigenesis.
Purpose of the Study:
- To review the role of alternative splicing in tumor regulatory cell death.
- To elucidate the mechanisms by which AS modulates various RCD modes.
- To summarize potential clinical applications of targeting AS-RCD pathways in cancer therapy.
Main Methods:
- Literature review focusing on alternative splicing and regulatory cell death.
- Analysis of molecular mechanisms linking AS to different RCD pathways.
- Synthesis of current research on clinical applications of AS-RCD targeting.
Main Results:
- AS plays a significant role in modulating diverse RCD pathways.
- Specific AS events and splicing factors are implicated in cancer progression via RCD.
- Targeting AS-RCD interactions presents a promising therapeutic strategy for cancer.
Conclusions:
- Alternative splicing is a key regulator of tumor cell death pathways.
- Understanding AS-mediated RCD offers mechanistic insights into tumorigenesis.
- Targeting AS-RCD axes holds potential for novel cancer treatments.
More Related Videos
Related Concept Videos
RNA Splicing
RNA Splicing
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Chromatin Structure Regulates pre-mRNA Processing
The chromatin structure, especially...
lncRNA - Long Non-coding RNAs
Experimental RNAi

